TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12959279
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril and doxazosin
Study: 2433701
Drug: Griseofulvin, 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin, 125 mg four times daily
Study: 2433701
Drug: Methisoprinol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methisoprinol, 1 g four times daily
Study: 2433701
Drug: Griseofulvin plus
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin plus methisoprinol (dosage schedules as above)
Study: 2433701
Drug: Placebo, four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, four times daily
Study: 26271769
Drug: Moderate Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Light (ML, 230 lx) for 120 min prior to and during exercise (2HEX)
Study: 26271769
Drug: Moderate Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Light (ML, 230 lx) for 60 min prior to and during exercise (1HEX)
Study: 26271769
Drug: Moderate Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Light (ML, 230 lx) for 60 min prior to exercise (1H)
Study: 24260184
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation (20 mg/day)
Study: 18510659
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER (4 mg)
Study: 1358231
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg muscimol (GABA agonist)
Study: 2951501
Drug: SR 270258
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 270258 (2 mg/m2, subcutaneous injections, three times per week for 1 month)
Study: 22034637
Drug: Pyridorin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridorin 150 mg twice daily
Study: 22034637
Drug: Pyridorin 300
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridorin 300 mg twice daily
Study: 16843455
Drug: metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (1 g twice daily)
Study: 23835717
Drug: 3D‐CRT APBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT APBI (38.5 Gy in 10 fractions twice daily)
Study: 23835717
Drug: WBI (42.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation)
Study: 19193900
Drug: D(2) receptor
Normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D(2) receptor agonist bromocriptine
Study: 1428296
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug administration)
Study: 8498314
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg daily
Study: 15343191
Drug: Amlodipine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (dose > or = 0.06 mg/kg per day)
Study: 9301693
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily) plus LHRH‐A
Study: 9301693
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH‐A
Study: 8359186
Drug: Thymoxamine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine 0.5% solution
Study: 8359186
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (mannitol)
Study: 8359186
Drug: Ibopamine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 1% solution
Study: 24561970
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day IV glutamine
Study: 24561970
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day enteral glutamine
Study: 24561970
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day IV and 15 g/day enteral glutamine
Study: 17452062
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Donepezil and Control)
Study: 12790207
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at target concentrations of 150, 225, and 300 ng mL(‐1)
Study: 12790207
Drug: Propofol added
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol added to alfentanil infusion
Study: 12790207
Drug: Alfentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil target concentration cA0 = 1240 (51) ng mL(‐1) and propofol concentration cP0 = 5.21 (0.36) microg mL(‐1)
Study: 1773095
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin (5 mg) at bedtime (2200 hr) for 3 weeks
Study: 1773095
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin (7 mg at 2100 hr)
Study: 7046937
Drug: Propranolol-hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-hydrochlorothiazide combination (n = 47)
Study: 24948511
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg once daily, orally)
Study: 24948511
Drug: Glimepiride (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-4 mg once daily, orally)
Study: 20104069
Drug: Citalopram (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20‐40 mg/day)
Study: 11488362
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75-225 mg/day)
Study: 3055720
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1 g carnitine orally for one week and 1 x 1 g carnitine for the following 7 days
Study: 24717908
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.1 μg/kg/min)
Study: 24717908
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (0.25 μg/kg/min)
Study: 22824930
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg for the first 3 days followed by 5 mg/day, reduced to 2.5 mg/day on the first postoperative day)
Study: 16327967
Drug: Daily visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily visit from a communicator/facilitator
Study: 11590503
Drug: Treatment combinations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment combinations of registered antiretroviral drugs (specific regimens not detailed)
Study: 29269937
Drug: Purified rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified rice endosperm protein (REP) supplementation (5 g/day for 4 weeks)
Study: 25693609
Drug: Revexepride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 0.1 mg three times daily
Study: 25693609
Drug: Revexepride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 0.5 mg three times daily
Study: 25693609
Drug: Revexepride 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 2.0 mg three times daily
Study: 20938767
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg/day) for up to 24 months
Study: 15695501
Drug: Bolus 5-FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5-FU/LV (5-FU 425 mg/m2 i.v. and LV 20 mg/m2 i.v. bolus days 1-5 every 28 days for 6 months)
Study: 15695501
Drug: PVI 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU (300 mg/m2/day for 12 weeks)
Study: 2853055
Drug: ICI 118551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551 25 mg
Study: 2853055
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg + ICI 118551 25 mg
Study: 2853055
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg + ICI 118551 25 mg
Study: 21052022
Drug: β-blocker or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker or diuretic monotherapy
Study: 21052022
Drug: β-blocker and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker and/or diuretic treatment
Study: 21052022
Drug: diltiazem treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem treatment
Study: 18569138
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg nightly for 14 nights (Control group)
Study: 18569138
Drug: Symptom-oriented hypnotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-oriented hypnotherapy, twice-a-week 1.5-hour sessions for 2 weeks (Intervention group)
Study: 14575233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ofloxacin and tinidazole
Study: 8806332
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) with adjunctive antithrombotic therapy (hirudin or heparin)
Study: 6824189
Drug: Pentoxifylline (Trental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (Trental 400 tablets with 400 mg active ingredient)
Study: 29724511
Drug: MenACWY-TT (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT (booster dose)
Study: 22802220
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (8‐ to 12‐week treadmill exercise program, target lactate 2.0±0.5 mmol/L)
Study: 10430379
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose octreotide (0.5 microg/kg/hr by continued i.v. infusion)
Study: 10430379
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose octreotide
Study: 2190515
Drug: Corticosteroids (prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisone, 60 mg/d for 7 days, followed by a progressive tapering over 14 days)
Study: 26208959
Drug: Bapineuzumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 0.5 mg/kg
Study: 20505438
Drug: Bapineuzumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 1.5 mg/kg
Study: 20505438
Drug: Bapineuzumab 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 5.0 mg/kg
Study: 30412493
Drug: Bapineuzumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab (all doses)
Study: 11832135
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin 1 microg x kg(‐1) x min(‐1) perioperatively
Study: 6733563
Drug: Intravenous misonidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous misonidazole with 10 fractions of 400 rad each
Study: 26691888
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg thrice-daily for 6 months
Study: 23276524
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Study: 15625142
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg ethinyl/estradiol plus 3 mg drospirenone (group A)
Study: 12413987
Drug: OGTT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT with IV injection of naloxone
Study: 12413987
Drug: HRT (estro‐progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (estro‐progestin combined therapy)
Study: 10207542
Drug: HIV-1 p24
Normalized name: HIV-1 p24 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 p24 antibody
Study: 10207542
Drug: HIV-1 p24
Normalized name: HIV-1 p24 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 p24 antibody < 5 RTU
Study: 30378288
Drug: Levosimendan infusions
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusions
Study: 28388244
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs in patients with relapsed and/or refractory MM
Study: 28388244
Drug: Novel anti-MM
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel anti-MM drugs
Study: 28388244
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies in the management of patients with newly diagnosed MM
Study: 22249393
Drug: Coffee enema
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee enema (3 times weekly for 6 visits)
Study: 22249393
Drug: Oral coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral coffee consumption (2 times daily for 11 days)
Study: 20305034
Drug: Gonadotropin-releasing hormone-analogues
Normalized name: Gonadotropin releasing hormone analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone-analogues (GnRH-a)
Study: 15663548
Drug: 22-oxacalcitriol (OCT)
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-oxacalcitriol (OCT) 5 microg, 10 microg, or 15 microg administered at the end of every HD for 12 weeks
Study: 15663548
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose OCT groups
Study: 7895356
Drug: Acetylcholine (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 micrograms/100 mL per minute)
Study: 7895356
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (1, 2, and 4 micrograms/100 mL per minute)
Study: 6947984
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml placebo (Group C)
Study: 6947984
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml 0.05% chlorhexidine digluconate (Group E)
Study: 6947984
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml 0.05% chlorhexidine digluconate (Group D)
Study: 26449252
Drug: anti-H.pylori treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-H.pylori treatment
Study: 26449252
Drug: anti-H.pylori followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-H.pylori followed by celecoxib treatment
Study: 15162156
Drug: Pain management
Normalized name: Olu Pain Management 4%-1% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain management (analgesic treatment)
Study: 9440175
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral LASIK
Study: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) < 30 mg/m2
Study: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) >= 30 - < 40 mg/m2
Study: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) >= 40 - < 50 mg/m2
Study: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) >= 50 - < 60 mg/m2
Study: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) >= 60 mg/m2
Study: 29307112
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day of chromium for 8 weeks
Study: 27494260
Drug: H2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 vaccine
Study: 27494260
Drug: hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatitis B vaccine
Study: 18387162
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol once weekly (Group 1)
Study: 18387162
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol twice weekly (Group 2)
Study: 16627223
Drug: ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ertapenem 1 g daily
Study: 16627223
Drug: piperacillin/tazobactam 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin/tazobactam 13.5 g daily in 3-4 divided doses
Study: 12682719
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg bolus followed by 12 mg/kg/h continuous infusion
Study: 1433889
Drug: Imipenem (IPM)
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem (IPM) (1.0‐1.5 g/day)
Study: 1433889
Drug: Aztreonam (AZT)
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam (AZT) (4 g/day) + Lincomycin (LCM) (1,200‐2,400 mg/day)
Study: 4008815
Drug: lodoxamide tromethamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lodoxamide tromethamine, 0.25 mg four times daily
Study: 27112322
Drug: Experimental agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agents in the MIDAS trial
Study: 27112322
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm with standard therapy
Study: 20875371
Drug: linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 10 mg/day
Study: 20875371
Drug: linagliptin and
Normalized name: linagliptin and empagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin and pioglitazone co-administration
Study: 14967867
Drug: Eucaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucaloric diet providing 8 g of CHO/kg of body weight
Study: 14967867
Drug: Eucaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucaloric diet providing 5 g of CHO/kg of body weight
Study: 14967867
Drug: Eucaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucaloric diet providing 3 g of CHO/kg of body weight
Study: 10930106
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 i.v. weekly
Study: 10930106
Drug: Leucovorin 100
Normalized name: leucovorin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-5, q 28 days
Study: 10930106
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 i.v. only day 1 + leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-3, q 28 days
Study: 1464655
Drug: Testosterone Only
Normalized name: Testosterone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Only group (200 mg testosterone enanthate weekly for 8 weeks)
Study: 1464655
Drug: Placebo/Testosterone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Testosterone group (placebo for first 4 weeks, then 200 mg testosterone enanthate weekly for next 4 weeks)
Study: 1464655
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (placebo injections for first 4 weeks)
Study: 28204882
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 50 µg
Study: 28204882
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes (sublingual and vaginal)
Study: 24528531
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bupivacaine plus 8 mg dexamethasone (active group)
Study: 24528531
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL saline (placebo group)
Study: 22743295
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d plus erlotinib 150 mg/d
Study: 22743295
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus erlotinib 150 mg/d
Study: 18330698
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg on days 1 and 29) + Exemestane (25 mg once daily for 8 weeks)
Study: 18330698
Drug: Triptorelin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin alone (3.75 mg on days 1 and 29)
Study: 11574775
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial chemotherapy exposure
Study: 11574775
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy response
Study: 9448611
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition through a central venous catheter (n = 20)
Study: 8073865
Drug: Nasal challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Study: 8073865
Drug: Oropharyngeal challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Study: 28744992
Drug: Carnosine 1
Normalized name: carnosine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine 1 g/day for 12 weeks
Study: 12492740
Drug: rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole (20 mg b.d.), amoxicillin (750 mg b.d.), metronidazole (250 mg b.d.) for 1 week
Study: 12492740
Drug: rabeprazole-amoxicillin-metronidazole
Normalized name: rabeprazole, amoxicillin and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole-amoxicillin-metronidazole
Study: 10594201
Drug: Prophylactic systemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic systemic antibiotics plus syringe pressure irrigation of the surgical wound with 300 ml of saline solution.
Study: 10594201
Drug: Prophylactic systemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic systemic antibiotics only (control group).